Conclusion In selected families, IHBW reduces hospital stay in managing NAS, without increasing morphine dose. Concerns regarding infant welfare limit the number of infants suitable for this management pathway.

**NEONATAL ABSTINENCE SYNDROME: HAS THE ONSET OF SYMPTOMS CHANGED IN THE LAST DECADE?**

doi:10.1136/archdischild-2012-302724.1054

C Smirk, E Bowman, LW Doyle, COF Kamlin. Royal Women’s Hospital, Parkville; Department of Obstetrics, University of Melbourne, Melbourne, VIC, Australia

**Background and Aims** Neonatal abstinence syndrome (NAS) often presents in the first 72 hours of life. Observation of at-risk infants is important to ensure prompt treatment if necessary. In 1998 at this hospital, 90% of infants requiring treatment for NAS commenced in the first week after birth. We aimed to describe the commencement of treatment for infants with NAS in the last decade.

**Methods** We undertook a retrospective review of babies treated pharmacologically for NAS during 2001–2010 at The Royal Women’s Hospital, Melbourne. Our guidelines recommend 7 days postnatal observation for infants at risk of NAS. Infants were admitted to the neonatal unit if they were felt to require treatment or had other neonatal complications.

**Results** 165 infants were treated for NAS; 85% and 8% of the mothers were hepatitis C and B positive respectively. In-utero substance exposure included opioids (97%), cannabis (29%) and benzodiazepines (25%). Over 90% of infants were treated by day 7 of life, most of whom had been admitted by day 5 (Figure). There were no differences in the age of treatment if the infant was exposed to opioids alone or multiple classes of drugs in utero.

**Conclusion** In the last decade, the timing of first medication for NAS is unchanged. Infants of chemically dependent mothers require tasarım.

**SYMPTOMS CHANGED IN THE LAST DECADE?**

doi:10.1136/archdischild-2012-302724.1055

M Yar, R Syed, WM Abou Al-Seoud. Neonatal Division, Paediatric Department; Paediatric Neurology Division, Paediatric Department, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia

**Background and Aim** The prenatal diagnosis of posterior fossa dysgenesis remains challenging.

**MEGA CISTERNA MAGNA DIAGNOSTIC DILEMMA**

doi:10.1136/archdischild-2012-302724.1056

Mega-cisterna magna (MCM) is applied to prominence of the retro-cerebellar CSF space and may not be associated with abnormalities. The clinical significance of this finding varies. Diagnostic modalities of the MCM are by ultrasound and or MRI. Our aim is to:

- Determine the Incidence of isolated dilated MCM in our population.
- Compare the accuracy of fetal ultrasound with postnatal neuroimaging.
- Report the associated central nervous system anomalies.

**Method** We identified retrospectively all reported cases of isolated dilated cisterna magna from 1/January 2007 till 31/7/2011.